Eurocine Vaccines has received authorization from the Swedish Medical Products Agency for a Phase 1/2 clinical study of its intranasal quadrivalent influenza vaccine Immunose Flu during the current flu season, the company said. Eurocine Vaccines also ran a Phase 1/2 study of Immunose Flu in 2016.
Immunose Flu is based on the company’s Endocine nasal vaccine adjuvant technology.
Eurocine Vaccines CEO Hans Arwidsson commented, “While this study is the next step on the path to create a better, more effective influenza vaccine for children, we intend to evaluate effects in the elderly – a population with a disproportionately high number of flu-related hospitalizations and deaths. Thereby we will generate both necessary safety data to reach our mission and, in addition, open for new business opportunities along the road.”
Results from the study are expected in the second half of 2018.
Read the Eurocine Vaccines press release.